Header Logo

Connection

Mindy Simpson to Male

This is a "connection" page, showing publications Mindy Simpson has written about Male.
Connection Strength

0.374
  1. Using an educational intervention to assess and improve disease-specific knowledge and health literacy and numeracy in adolescents and young adults with haemophilia A and B. Haemophilia. 2021 Mar; 27(2):229-236.
    View in: PubMed
    Score: 0.057
  2. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis. Thromb Haemost. 2021 08; 121(8):1079-1086.
    View in: PubMed
    Score: 0.056
  3. Comparing Physician and Patient Perspectives on Prophylactic Treatment with BAY?94-9027 for Severe Haemophilia?A: A Post Hoc Analysis. Adv Ther. 2020 06; 37(6):2763-2776.
    View in: PubMed
    Score: 0.054
  4. Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products. J Manag Care Spec Pharm. 2020 Apr; 26(4):504-512.
    View in: PubMed
    Score: 0.053
  5. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis. J Thromb Haemost. 2018 01; 16(1):39-43.
    View in: PubMed
    Score: 0.023
  6. Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis. Blood. 2017 10 12; 130(15):1757-1759.
    View in: PubMed
    Score: 0.022
  7. Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A. Blood. 2017 03 09; 129(10):1245-1250.
    View in: PubMed
    Score: 0.021
  8. Sickle Cell Trait Testing Should Not Be a Player in NCAA Athletics: Examining the Media's Role in Disseminating Awareness and Information. J Pediatr Hematol Oncol. 2018 07; 40(5):414-415.
    View in: PubMed
    Score: 0.012
  9. Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors. Haemophilia. 2017 Nov; 23(6):844-851.
    View in: PubMed
    Score: 0.011
  10. Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors. Cochrane Database Syst Rev. 2017 09 25; 9:CD011441.
    View in: PubMed
    Score: 0.011
  11. PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding. Haemophilia. 2017 Nov; 23(6):832-843.
    View in: PubMed
    Score: 0.011
  12. Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(?) ) in patients with severe haemophilia A. Haemophilia. 2016 Sep; 22(5):730-8.
    View in: PubMed
    Score: 0.010
  13. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016 May 26; 374(21):2054-64.
    View in: PubMed
    Score: 0.010
  14. Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the?Kids-DOTT trial): pilot/feasibility phase findings. J Thromb Haemost. 2015 Sep; 13(9):1597-605.
    View in: PubMed
    Score: 0.010
  15. Use of global assays to understand clinical phenotype in congenital factor VII deficiency. Haemophilia. 2013 Sep; 19(5):765-72.
    View in: PubMed
    Score: 0.008
  16. Vascular compromise as a cause of sudden death in a pediatric patient with widely metastatic testicular germ cell tumor. J Pediatr Hematol Oncol. 2009 Oct; 31(10):756-7.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.